Auditors ranked for biotech and life sciences companies whose audits routinely overlap with HIPAA, HITRUST, and 21 CFR Part 11 considerations.
How we picked: Auditors ranked for biotech and life sciences companies whose audits routinely overlap with HIPAA, HITRUST, and 21 CFR Part 11 considerations.
We filtered for AICPA-licensed firms with HIPAA in services offered AND healthcare or healthtech in industriesServed. Firms with HITRUST CSF Assessor accreditation ranked higher because biotech buyers selling into health systems frequently need both. We deprioritized firms whose primary industry focus is non-life-sciences (e.g., real estate, hospitality).
Best for: Mid-market and enterprise biotech with HITRUST + SOC 2 needs
Pricing: Contact for pricing
Best for: Biotech needing SOC 2, HIPAA, and HITRUST from a single multi-accredited firm
Pricing: Contact for pricing
Best for: Mid-market biotech wanting a confirmed-pass boutique with HITRUST capability
Pricing: Contact for pricing
Best for: SMB biotech with HIPAA + SOC 2 needs and predictable timeline
Pricing: Contact for pricing
Best for: Newer biotech startups wanting young boutique with HIPAA/HITRUST capability
Pricing: Contact for pricing
Best for: Startup-stage biotech wanting a boutique with HIPAA capability
Pricing: Contact for pricing
Big Four firms have biotech-industry expertise but the entry price is generally not justified for a typical biotech SOC 2 unless consolidating with an existing Big Four financial-statement audit. Sensiba serves a broader client base (real estate, agribusiness, hospitality) — biotech buyers will get more specialist engagement teams elsewhere. Risk3sixty is SaaS-focused rather than life-sciences-focused.